IJCRR - 7(4), February, 2015
PROTEIN ENERGY WASTING (PEW) / CACHEXIA IN CHRONIC KIDNEY DISEASE - ROLE OF LEPTIN AND INSULIN
Author: D. Ponnudhali, P. Nagarajan, R. Shankar
Background: The prevalence of protein energy wasting (PEW)/ cachexia is very high among patients with chronic kidney disease (PEW), increasing in severity with the progression of the disease. Among other factors, increased serum Leptin levels and insulin resistance have been implicated in the pathogenesis of PEW/cachexia in CKD
Aim and objectives: To assess the serum leptin & insulin levels along with HOMA IR (Homeostasis model assessment-Insulin Resistance) in non diabetic chronic kidney disease patients and to study the correlation of these parameters with glomerular filtration rate (GFR) & body mass index (BMI).
Materials and methods: Non-diabetic CKD patients (group1; n=45) and healthy non-diabetic individuals (group 2; n=45) with normal renal function were recruited for the study. Serum leptin and Insulin levels were assessed using ELISA kits. Calculated values of HOMA IR & BMI were taken for the analyses.Statistical analysis: The statistical analysis was done using SPSS version 16. The parameters were compared among the 2 groups using Independent t test and correlation coefficient.
Results: Serum Leptin levels (24.15 ± 17.44 ng/ml) were increased significantly (p=.000) in group 1 patients compared to those in group 2 (7.50 ± 1.28 ng/ml). Serum insulin levels (p=.000) were increased in CKD patients (15.49 ± 9.39 μU/ml) from that of the healthy controls (7.50 ± 1.28μU/ml). The HOMA IR was also significantly high (p=0.000) in the CKD group ( 3.69 ± 2.26) than the controls (1.69 ± 0.35). Leptin, insulin & HOMA IR showed a highly significant negative correlation with GFR & BMI .The serum albumin and total cholesterol in the CKD group were 3.20 ± 0.19 g/dl & 127.47 ± 31.75 mg/dl respectively.
Conclusion: Hyperleptinemia and insulin resistance may be responsible for protein energy wasting/cachexia associated with CKD.
Keywords: Leptin, protein energy wasting (PEW), Cachexia, Insulin resistance
D. Ponnudhali, P. Nagarajan, R. Shankar. PROTEIN ENERGY WASTING (PEW) / CACHEXIA IN CHRONIC KIDNEY DISEASE - ROLE OF LEPTIN AND INSULIN International Journal of Current Research and Review. 7(4), February, 54-59
1. Fouque D, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int.2008;73:391-8.
2. Sarraf P, Frederich RC, Turner EM et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia.J Exp Med 1997;185:171- 175
3. Eidemak I, Feldt-Rasmussen B, Kanstrup IL et al. Insulin resistance and hyperinsulinemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia.1995; 38: 565–57.
4. Wai Cheung, Pin X. Yu, Brian M. Little, Roger D. Cone, Daniel L. Marks, and Robert H. Mak. Role of leptin and melanocortin signalling in uremia-associated cachexia. J. Clin. Invest. 2005;115 :1659–1665.
5. Pecoits-Filho R, Nordfors L, Heimburger O et al. Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur J Clin Invest. 2002; 32: 811–817.
6. RateGraham RD Jones and Ee-Mun Lim. The National Kidney Foundation Guideline on Estimation of the Glomerular Filtration.Clin Biochem Rev. Aug 2003; 24(3): 95–98.
7. Nazish Rafique, Mohammad Nasir Afzal. Relationship of serum leptin levels with body mass index and gender . RMJ. 2009; 34(2): 164-166.
8. A Piyali das et al. Association of obesity and leptin with insulin resistance in type 2 diabetes mellitus in indian population. Indian J Physiol Pharmacol. 2013; 57(1): 45–50.
9. Ali Movahed et al. Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients. Evidence-Based Complementary and Alternative Medicine. Volume 2013, 1-11.
10. Wieneke Marleen Michels et al. Performance of the Cockcroft-Gault, MDRD, and New CKDEPI Formulas in Relation to GFR, Age, and Body Size. Clin J Am Soc Nephrol. 2010; 5:1003–1009.
11. Yashpal P. Jadeja, Vijay Kher. Protein energy wasting in chronic kidney disease: An update with focus on nutritional interventions to improve outcomes Indian Journal of Endocrinology and Metabolism / Mar-Apr 2012 / Vol 16 | Issue.
12. Kronenberg. F et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11: 105–1
13. RH Mak, W Cheung, RD Cone and DL Marks. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney International .2006; 69:794–797.
14. G. H. Lee, R. Proenca, J. M. Montez et al. “Abnormal splicing of the leptin receptor in diabetic mice.” Nature.1996; vol 379,(6566): 632–635.
15. Relationship between Plasma Leptin Level and Chronic Kidney Disease. Anoop Shankar, Shirmila Syamala, Jie Xiao, and Paul Muntner. International Journal of Nephrology.Volume 2012; Article ID 2 69532, 6 pages.
16. Cumin F, Baum HP, De Gasparo M, Levens N. Leptin is cleared from the circulation primarily by the kidney. Int J obes Relat Metab Disord.1997;21:495–504.
17. Sharma K, Considine RV, Michael B et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int.1997; 51:1980–1985.
18. Pinto, S., et al. Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science. 2004; 304:110–115.
19. Schwartz, M.W., et al. Central nervous system control of food intake. Nature.2000; 404: 661–671.
20. M. G. Castro and E. Morrison, “Post-translational processing of pro- opiomelanocortin in the pituitary and in the brain,” Critical Reviews in Neurobiology.1997; vol 11, no 1: 35–57.
21. Mak RH. Insulin resistance but IGF-I sensitivity in chronic renal failure. Am J Physiol 1996; 271: F114– F119.
22. P. Leroy, S. Dessolin, P. Villageois et al., “Expression of ob gene in adipose cells: regulation by insulin,”Journal of Biological Chemistry.1996; vol. 271(5): 2365–2368.
23. May RC, Kelly RA, Mitch WE. Mechanisms for defects in muscle protein metabolism in rats with chronic uremia: The influence of metabolic acidosis. J.Clin Invest 1987;79: 1099-1103.
24. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T.Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis.2005; 45:275–280.
25. Jie Du et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J. Clin. Invest. 2004;113: 115–123
26. James L. Bailey et al. Chronic Kidney Disease Causes Defects in Signaling through the Insulin Receptor Substrate/ Phosphatidylinositol 3-Kinase/Akt Pathway: Implications for Muscle Atrophy. J Am Soc Nephrol.2006;17: 1388– 1394.
27. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med.1996; 335:1897–1905.
28. Bin Zheng et al. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J. 2010;24: 2660 –2669.
29. LeeSW, DaiG ,HuZ, WangX, DuJ, MitchWE. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol.2004;15:1537–1545.
30. Solomon, V., and Goldberg, A.L. Importance of the ATPubiquitin- proteasome pathway in degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J. Biol. Chem. 1996;271:26690–26697.
31. Slew ED, Ikizler TA. Dietary concerns in advanced chronic kidney disease: insulin resistance and protein energy metabolism in advanced chronic kidney disease. Semin Nephrol. 2007; 23:378 – 82. 32. N. Werner and G. Nickenig, “From fat fighter to risk factor: the zigzag trek of leptin,”
Arteriosclerosis, Thrombosis, and Vascular Biology.2004; vol. 24(1): 7–9.
33. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol. 2003; 284(6):F1121-37.